Cat. No.: HY-10402

Losmapimod

(Synonyms: GSK-AHAB; GW856553X; SB856553)

12 Cited Publications

Customer Review

Based on 12 publication(s) in Google Scholar

Losmapimod (GSK-AHAB; GW856553X) is an orally active p38α/β MAPK inhibitor, with pK_i values of 8.1 and 7.6 for p38α and p38β, respectively. Losmapimod reduces DUX4 expression, thus exerting efficacy in facioscapulohumeral muscular dystrophy. By inhibiting MAPK/NF-κB, Losmapimod reduces apoptosis of epileptiform hippocampal neurons, and exhibits anti-allodynia and anti-hyperalgesic activities. Losmapimod blocks the entry and fusion of Lassa fever virus (LASV). Losmapimod overcomes tyrosine kinase inhibitor resistance in non-small cell lung cancer (NSCLC). Losmapimod inhibits myocardial senescence and inflammation, and possesses cardioprotective activity against cardiotoxicity.

For research use only. We do not sell to patients.

Purity: 99.94%
CAS No.: 585543-15-3
Formula: C₂₂H₂₆FN₃O₂
Molecular Weight:383.46

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Losmapimod Chemical Structure

CAS No.: 585543-15-3

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (12)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

All p38 MAPK Isoforms :

All NF-κB Isoforms :

In Vitro

Losmapimod (0.1-10 μM; 48.25 h) potently inhibits LASV-GP (strain Josiah)/HIV-luc pseudovirus infection in HEK293T cells with an EC₅₀ of 3.68 μM^[2].
Losmapimod (0.02-50 μM; 73 h) effectively inhibits authentic LASV (strain Josiah) infection in Vero E6 cells, with EC₅₀ values of 2.18 μM (TCID₅₀) and 0.71 μM (RT-qPCR)^[2].
Losmapimod (30 μM; 48.25 h) inhibits infection by LASV-GP/HIV-luc pseudoviruses from four distinct LASV lineages in HEK293T cells, with EC₅₀ values ranging from 0.9 μM to 2.7 μM^[2].
Losmapimod (30 μM) blocks LASV-GP (strain Josiah)/HIV-luc pseudovirus infection in U-87 MG cells exclusively at the post-attachment viral fusion step^[2].
Losmapimod (10 μM) specifically inhibits low pH-triggered LASV-GP (strain Josiah) mediated cell-cell fusion in HEK293T cells when added prior to pH exposure^[2].
Losmapimod (3-30 μM) dose-dependently inhibits LASV-GP (strain Josiah) mediated cell-cell fusion in co-cultured HEK293T and U-87 MG cells, with significant inhibition observed at concentrations as low as 3 μM^[2].
Losmapimod (0.3-30 μM; 48.25 h) inhibits LASV-GP (strain Josiah)/HIV-luc pseudovirus infection in HEK293T cells by targeting the SSP-GP2 interface, as it is ineffective against pseudoviruses with LASV SSP and transmembrane domains replaced by LCMV sequences^[2].
Losmapimod (1 μM; 24 h) eliminates gefitinib-induced tetraploidization in Gefitinib (HY-50895)-resistant HCC827GR and H1975 human lung adenocarcinoma cells when used in combination with 1 μM gefitinib^[4].
Losmapimod (1 μM; 10-24 h) inhibits gefitinib-induced activation of the p38 MAPK-STAT3 pathway and subsequent up-regulation of p21 and cyclin D1 in Gefitinib-resistant HCC827GR and H1975 human lung adenocarcinoma cells when used in combination with 1 μM gefitinib^[4].
Losmapimod (1 μM; 3 weeks) in combination with 1 μM Gefitinib significantly inhibits anchorage-independent growth of gefitinib-resistant HCC827GR and H1975 human lung adenocarcinoma cells^[4].
Losmapimod (1 μM; 72 h) in combination with 1 μM gefitinib synergistically reduces viability of Gefitinib-resistant HCC827GR (combination index 0.14) and H1975 (combination index 0.22) human lung adenocarcinoma cells^[4].
Losmapimod (1 μM; 3 h) reduces apoptosis, inhibits MAPK/NF-κB signaling activation, and suppresses inflammatory factor production in epileptiform human hippocampal neurons, with no harmful effects on normal human hippocampal neurons^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis^[4]

Cell Line:

gefitinib-resistant HCC827GR and H1975 human lung adenocarcinoma cells
Concentration:

1 μM (in combination with 1 μM Gefitinib)
Incubation Time:

24 h
Result:

Eliminated gefitinib-induced tetraploidization, as measured by the disappearance of the tetraploid (G1) cell subpopulation in flow cytometry analysis.

Western Blot Analysis^[4]

Cell Line:

gefitinib-resistant HCC827GR and H1975 human lung adenocarcinoma cells
Concentration:

1 μM (either alone or in combination with 1 μM Gefitinib)
Incubation Time:

2 h, 6 h, 10 h, 24 h
Result:

Inhibited gefitinib-induced phosphorylation of p38 MAPK at 10 h in both cell lines.
Did not alter gefitinib-induced phosphorylation of YAP at 2 h or MKK3/6 at 6 h, and further up-regulated gefitinib-induced MKK3/6 phosphorylation.
Inhibited gefitinib-induced phosphorylation of STAT3 at 10 h, as well as gefitinib-induced up-regulation of p21 at 10 h and cyclin D1 at 24 h in both cell lines.

Cell Viability Assay^[4]

Cell Line:

gefitinib-resistant HCC827GR and H1975 human lung adenocarcinoma cells
Concentration:

1 μM (in combination with 1 μM gefitinib)
Incubation Time:

72 h
Result:

Reduced cell viability to approximately 75% in HCC827GR cells and approximately 70% in H1975 cells, while losmapimod or gefitinib alone had no inhibitory effect.
Synergistically inhibited cell proliferation with a combination index of 0.14 for HCC827GR cells and 0.22 for H1975 cells.

Apoptosis Analysis^[5]

Cell Line:

human hippocampal neurons
Concentration:

1 μM
Incubation Time:

3 h
Result:

Reduced the apoptosis rate of epileptiform human hippocampal neurons from ~17% to ~8%.
Reversed the upregulation of Bax and cleaved caspase 3, and the downregulation of Bcl-2 in epileptiform neurons.
Inhibited the increased phosphorylation of p38 and IκB, and restored reduced IκB expression in epileptiform neurons.
Suppressed the elevated levels of TNF-α, IL-1β, IL-6, IL-10, and CRP in epileptiform neurons.
Showed no significant effect on normal neurons.

In Vivo

Losmapimod (12 mg/kg/day; p.o.; continuous; 6 weeks) ameliorates Doxorubicin (HY-15142A)-induced chronic cardiac dysfunction, mitigates senescence and cardiac inflammation, and upregulates mitochondrial fusion-related gene expression in male C57BL/6 N mice by inhibiting p38 MAPK activation^[3].
Losmapimod (1.8 mg/kg; i.p.; once daily; 3 days) protects against Pilocarpine (HY-B0726A)-induced epilepsy in Sprague-Dawley rats by inhibiting MAPK/NF-κB pathway activation, reducing neuronal apoptosis and inflammation, restoring synaptic receptor expression, improving seizure parameters, and reversing cognitive deficits^[5].
Losmapimod (2-50 mg/kg; p.o.; once daily; Day 0 to Day 2) produces dose-dependent antiallodynic and antihyperalgesic effects in Carrageenan-induced acute pain, with an ED₅₀ of 6.8 mg/kg for mechanical allodynia and 3.4 mg/kg for thermal hyperalgesia, and inhibits early neuronal and microglial p38 activation^[6].
Losmapimod (30 mg/kg; p.o.; once daily; Day 0 to Day 2) provides significant antinociceptive effects in plantar incision-induced postoperative pain^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6N (male, 4 weeks old, acclimated for 1 week prior to study, chronic doxorubicin-induced cardiotoxicity model)^[3]
Dosage:

12 mg/kg/day
Administration:

p.o.; continuous; 4 days pre-doxorubicin plus 6-week doxorubicin treatment period
Result:

Attenuated doxorubicin-induced reduction in left ventricular ejection fraction, fractional shortening, and heart rate.
Mitigated doxorubicin-induced upregulation of cardiac Nppb (brain natriuretic peptide) gene expression.
Abrogated doxorubicin-induced upregulation of the senescence marker p21^Cip1 in both heart and liver tissue.
Reduced doxorubicin-induced upregulation of cardiac Il-1α and Il-6 gene expression.
Decreased serum IL-6 and CXCL1 levels in both saline- and doxorubicin-treated mice compared to control diet groups.
Significantly upregulated cardiac mitofusin2 (Mfn2) gene expression in both saline- and doxorubicin-treated mice.
Attenuated p38 MAPK activation in both heart and liver tissue of saline- and doxorubicin-treated mice.
Increased JNK activation in heart and liver tissue of saline-treated mice; doxorubicin reduced this effect in the liver but not the heart.
No significant effect on doxorubicin-induced cardiac atrophy (heart weight/tibia length ratio).

Animal Model:

Sprague-Dawley (adult male, 6-8 weeks old, 180-220 g, epilepsy induced by subcutaneous methylscopolamine pre-treatment followed by intraperitoneal pilocarpine injections to induce status epilepticus)^[5]
Dosage:

1.8 mg/kg
Administration:

i.p.; once daily; 3 days
Result:

Increased Nissl-positive cell count in the hippocampal CA3 region from ~170 to ~230.
Decreased hippocampal neuron apoptosis rate from ~17% to ~10%.
Reversed SE-induced upregulation of Bax and cleaved caspase-3, and downregulation of Bcl-2.
Reduced SE-induced increases in p-p38 and p-IκB protein expression, and restored IκB protein levels.
Reduced SE-induced upregulation of IL-6, TNF-α, IL-1β, IL-10, and CRP in hippocampal tissue.
Partly reversed SE-induced upregulation of NMDAR subunits (NR1A, NR2A, NR2B, NR2C, NR2D) and AMPAR GRIA2 subunit gene expression.
Increased incubation period of clonic cramp to 92.8 s, transition time to 40.1 s, and incubation period of tetanic convulsion to 126.9 s.
Reduced rate of tetanic convulsions from ~100% to ~65%.
Reduced mean escape latency and mean path length in the Morris water maze.
Increased time spent in the target quadrant and number of platform crossings compared to SE alone rats.

Animal Model:

Sprague-Dawley (male, 280-300 g, acute pain model via 3% carrageenan subcutaneous injection in left hind paw)^[6]
Dosage:

2 mg/kg; 4 mg/kg; 12 mg/kg; 50 mg/kg
Administration:

p.o.; once daily; Day 0 to Day 2
Result:

Reversed carrageenan-induced mechanical allodynia and thermal hyperalgesia with efficacy similar to morphine at 12 mg/kg.
Reached an ED₆₄ for mechanical allodynia and ED₇₈ for thermal hyperalgesia at 12 mg/kg.
Yielded an ED₅₀ of 6.8 mg/kg for mechanical allodynia and 3.4 mg/kg for thermal hyperalgesia from dose-response curve.
Significantly increased paw withdrawal thresholds to mechanical and thermal stimulation compared to baseline.
Reduced the percentage of activated p-p38-expressing DRG neurones from 90% to 50% at 2 hours after carrageenan injection.
Reduced the number of activated p-p38-expressing ipsilateral spinal cord microglial cells from 43 to 20 at 15 hours after carrageenan injection.
Showed no effect on astrocytic activation at any time point.

Animal Model:

Sprague-Dawley (male, 280-300 g, postoperative pain model via plantar incision)^[6]
Dosage:

30 mg/kg
Administration:

p.o.; once daily; Day 0 to Day 2
Result:

Significantly reversed plantar incision-induced allodynia and hyperalgesia, enhancing paw withdrawal thresholds compared to incision-only controls.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 585543-15-3
Appearance Solid
Molecular Weight 383.46
Formula C₂₂H₂₆FN₃O₂
Color White to off-white
SMILES

CC1=C(C2=NC=C(C(NCC(C)(C)C)=O)C=C2)C=C(C(NC3CC3)=O)C=C1F
Synonyms

GSK-AHAB; GW856553X; SB856553
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (12)

All WBFlow CytometryCell Proliferation/Viability AssayIn Vivo Efficacy StudyIHC

Sort by:

Journal Impact Factor

J Exp Clin Cancer Res

Pulmonary interleukin 1 beta/serum amyloid A3 axis promotes lung metastasis of hepatocellular carcinoma by facilitating the pre-metastatic niche formation. [Abstract]

2023 Jul 13;42(1):166. PMID: 37443052
EBioMedicine

Losmapimod Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer by Preventing Tetraploidization. [Abstract]

2018 Feb:28:51-61. PMID: 29398601

Losmapimod purchased from MedChemExpress. Usage Cited in: EBioMedicine. 2018 Feb:28:51-61. [Abstract]

Western blot analysis of p-YAP, p-MKK3/6 and p-p38 expressions in untreated ZD1839-resistant cells (left, HCC827GR and right, H1975) or cells treated for 2, 6 or 10 h with ZD1839 (1 μM) or Losmapimod (1 μM) either alone or in combination. Total YAP, MKK3/6 and p38 MAPK proteins are used as loading controls.

Losmapimod purchased from MedChemExpress. Usage Cited in: EBioMedicine. 2018 Feb:28:51-61. [Abstract]

Losmapimod (1 μM; 24 h) could eliminate gefitinib-induced tetraploidy in both resistant cell lines (left, HCC827GR and right, H1975).

Losmapimod purchased from MedChemExpress. Usage Cited in: EBioMedicine. 2018 Feb:28:51-61. [Abstract]

Losmapimod (1 μM; 24 h) phosphorylation of STAT3 and expressions of p21 and cyclin D1 were up-regulated with gefitinib treatment in both resistant cell lines, and that the up-regulations could be inhibited by losmapimod (left, HCC827GR and right, H1975).

Losmapimod purchased from MedChemExpress. Usage Cited in: EBioMedicine. 2018 Feb:28:51-61. [Abstract]

Losmapimod (72 h) did not inhibit cell viability in HCC827GR and H1975 cells.

Losmapimod purchased from MedChemExpress. Usage Cited in: EBioMedicine. 2018 Feb:28:51-61. [Abstract]

Losmapimod (12 mg/kg; daily; PO; for 15 days) alone or in combination with gefitinib markedly reduced gefitinib-resistant NSCLC PDX tumor volume and weight; no changes in mouse body weight were observed.

Losmapimod purchased from MedChemExpress. Usage Cited in: EBioMedicine. 2018 Feb:28:51-61. [Abstract]

Losmapimod (12 mg/kg; daily; PO; for 15 days) significantly reduced cyclin D1, p-p38 and Ki-67 expression in xenograft tissues.
Cell Commun Signal

Staphylococcus aureus vesicles impair cutaneous wound healing through p38 MAPK-MerTK cleavage-mediated inhibition of macrophage efferocytosis. [Abstract]

2025 Jan 8;23(1):14. PMID: 39780180
EMBO Mol Med

Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance. [Abstract]

2023 Mar 8;15(3):e16235. PMID: 36652375

Losmapimod purchased from MedChemExpress. Usage Cited in: EMBO Mol Med. 2023 Mar 8;15(3):e16235. [Abstract]

Losmapimod (10 μM) inhibited p38 activity and prevented thiaparib-induced p‐STAT1 in JeKo‐1 and THP‐1 cells.
Cell Syst

A Library of Phosphoproteomic and Chromatin Signatures for Characterizing Cellular Responses to Drug Perturbations. [Abstract]

2018 Apr 25;6(4):424-443.e7. PMID: 29655704
Cell Mol Life Sci

Global phosphoproteomic analysis identified key kinases regulating male meiosis in mouse. [Abstract]

2022 Aug 5;79(8):467. PMID: 35930080
J Cell Mol Med

Phosphorylated MAPK11 promotes the progression of clear cell renal cell carcinoma by maintaining RUNX2 protein abundance. [Abstract]

2023 Sep;27(17):2583-2593. PMID: 37525479
Neurochem Int

Suppression of mitochondrial fission in experimental cerebral ischemia: The potential neuroprotective target of p38 MAPK inhibition. [Abstract]

2015 Nov;90:1-8. PMID: 26116440

Losmapimod purchased from MedChemExpress. Usage Cited in: Neurochem Int. 2015 Nov;90:1-8. [Abstract]

Inhibition of p38 MAPK (p38 inhibitor, Losmapimod 1 mg/kg) suppressed DLP1 and MFF with the temporal-accumulated effect after ischemia-reperfusion.
Aging (Albany NY)

Senescence-associated hyper-activation to inflammatory stimuli in vitro. [Abstract]

2021 Aug 10;13(15):19088-19107. PMID: 34375950
Am J Physiol Lung Cell Mol Physiol

Cigarette smoke and its component acrolein augment IL-8/CXCL8 mRNA stability via p38 MAPK/MK2 signaling in human pulmonary cells. [Abstract]

2012 Nov 15;303(10):L929-38. PMID: 22983351
Leuk Lymphoma

Trametinib enhances ATRA-induced differentiation in AML cells. [Abstract]

2021 Dec;62(14):3361-3372. PMID: 34355652
Patent

US20180296546A1.

Solvent & Solubility

In Vitro:

Ethanol : 33.33 mg/mL (86.92 mM; Need ultrasonic)

DMSO : 25 mg/mL (65.20 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.6078 mL

13.0392 mL

26.0783 mL

5 mM

0.5216 mL

2.6078 mL

5.2157 mL

10 mM

0.2608 mL

1.3039 mL

2.6078 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.52 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.52 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 3

Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (6.52 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 4

Add each solvent one by one: 10% EtOH 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.52 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (292 KB)
SDS (418 KB)
- English - EN (418 KB)
- Français - FR (418 KB)
- Deutsch - DE (418 KB)
- Norwegian - NO (418 KB)
- Español - ES (418 KB)
- Swedish - SV (418 KB)
- Italian - IT (418 KB)
- Korean - KR (418 KB)
- Portuguese - PT (418 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Tawil R, et al. Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial. Lancet Neurol. 2024 May;23(5):477-486.
[Content Brief]

[2]. Zhang X, et al. Identification of a clinical compound losmapimod that blocks Lassa virus entry. Antiviral research. 2019 Jul;167:68-77. [Content Brief]

[3]. Dabour MS, et al. Losmapimod ameliorates doxorubicin-induced cardiotoxicity through attenuating senescence and inflammatory pathways. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2024 Oct;179:117288. [Content Brief]

[4]. Yeung YT, et al. Losmapimod Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer by Preventing Tetraploidization. EBioMedicine. 2018 Feb;28:51-61. [Content Brief]

[5]. Li M, et al. Losmapimod Protected Epileptic Rats From Hippocampal Neuron Damage Through Inhibition of the MAPK Pathway. Frontiers in pharmacology. 2019;10:625. [Content Brief]

[6]. Soued M, et al. Antinociceptive properties of losmapimod in two acute pain models in rats: behavioural analysis, immunohistochemistry, dose response, and comparison with usual analgesic drugs. BJA Open. 2022 Aug 17;3:100029.
[Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / Ethanol	1 mM	2.6078 mL	13.0392 mL	26.0783 mL	65.1958 mL
	5 mM	0.5216 mL	2.6078 mL	5.2157 mL	13.0392 mL
	10 mM	0.2608 mL	1.3039 mL	2.6078 mL	6.5196 mL
	15 mM	0.1739 mL	0.8693 mL	1.7386 mL	4.3464 mL
	20 mM	0.1304 mL	0.6520 mL	1.3039 mL	3.2598 mL
	25 mM	0.1043 mL	0.5216 mL	1.0431 mL	2.6078 mL
	30 mM	0.0869 mL	0.4346 mL	0.8693 mL	2.1732 mL
	40 mM	0.0652 mL	0.3260 mL	0.6520 mL	1.6299 mL
	50 mM	0.0522 mL	0.2608 mL	0.5216 mL	1.3039 mL
	60 mM	0.0435 mL	0.2173 mL	0.4346 mL	1.0866 mL
Ethanol	80 mM	0.0326 mL	0.1630 mL	0.3260 mL	0.8149 mL

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Losmapimod

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Autophagy Compound Library

Drug Repurposing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Pyroptosis Compound Library

Orally Active Compound Library

Anti-Lung Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Rare Diseases Drug Library

Antidepressant Compound Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Highly Selective Inhibitors Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Ovarian Cancer Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

Posttranslational Modification Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Losmapimod

All p38 MAPK Isoforms

All NF-κB Isoforms

Biological Activity

Chemical Information

Publications (12)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Losmapimod Related Classifications

Cat. No.: HY-10402